OV-3133(R) cell line

Epithelial ovarian cancer cell lines spontaneously derived from ascites of patient diagnosed with high-grade serous ovarian cancer

Contributors

Inventor Institute
Anne-Marie Mes-Masson and Diane Provencher Centre Hospitalier de L’université de Montréal
Cat. #: 161782
Cancer types: Gynaecologic cancer
Research Fields: Cancer
Organism: Human
Tissue: Derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse
Gender: Female
Morphology: Formed tumors at subcutaneous sites in SCID mice. No expressionof the tumor suppressor p53 detected. Strong HER2 expression detected in protein extracts and observed in solid tissues by IHC. Spheroid formation: no
Growth properties: Adherent
Primary citation: Létourneau et al. 2012. BMC Cancer. (12): 379. PMID: 22931248
Alternate name: OV-3133(R)
Product description: Epithelial ovarian cancer cell lines spontaneously derived from ascites of patient diagnosed with high-grade serous ovarian cancer at specific time points at diagnosis and relapse (R). Primary treatment included paclitaxel and carboplatin and later treatment included doxorubicin, carboplatin, gemcitabine, and etoposide.
Gender: Female
CRISPR: No
Production details: Established from the cellular fraction of ascites collected by centrifugation. The cell lines were then maintained for 40 days in OSE with medium replaced weekly.
Additional notes: Patient 3133 received treatment of paclitaxel and carboplatin 1-3 months after sugery and confirmation of ovarian cancer diagnosis. A second sugery 6 months after the first detectede infiltration of the tumor in part of the abdomen. Patient was treated with dxorubicin and later carboplatin and gemcitabine after no significant changes of CA-125 levels were seen. Later imaging presented an increase in tumor mass whereby she was given etoposide orally for eight days.
Receptors of note: No
Growth medium: OSE medium contains 10% FBS, 0.5ug/mL amphotericin B and 50 ug/mL gentamicin
Atmosphere: Hypoxic condition of 5%O2 and 5%CO2
References:

Tomas et al. 2023. J Ovarian Res. 11

16(1):70. PMID: 37038202 Vias et al. 2023. Elife. 11

12:e83867. PMID: 37166279 Jubelin et al. 2022. Cell Biosci. 11

12(1):155. PMID: 36089610 Canals et al. 2022. Front Oncol. 4

12:856424. PMID: 35600398

Related Tools for Cell lines

Cat. # Tool Name
151014 MCF7 AREc32 Cell Line Key Info View Tool
151446 FLYRD18 Cell Line Key Info View Tool
151463 Omega-E Packaging Cell Line Key Info View Tool
151629 MEF Raf1 FF/FF KI Cell Line Key Info View Tool
151655 FLYA-13 Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.